Clinical Trial Update: Nicotinamide Riboside in LVAD Recipients [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 study evaluating nicotinamide riboside in LVAD recipients with advanced heart failure has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Nicotinamide Riboside (nicotinamide riboside)

Snippet

Sponsor: University of Washington | Conditions: Heart Failure，Congestive, Heart Failure New York Heart Association Class IV | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2024-09-20